ThomasJWeberMD

Endocrinology • Durham, NC

Osteoporosis & Bone Metabolism Medicine, Parathyroid

Professor of Medicine, Duke University

Join to view full profile

Dr. Weber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weber's full profile

Already have an account?

Office
40 Duke Medicine Cir
Durham, NC 27710
Phone+1 919-668-1367

Fax+1 919-668-1366

Education & Training

Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1993 - 1997
Yale-New Haven Medical CenterResidency, Internal Medicine, 1989 - 1992
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1989

Certifications & Licensure

NC State Medical License 1994 - 2025
PA State Medical License 2002 - 2002
CT State Medical License 1992 - 1993
OH State Medical License 1990 - 1992
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

9 citations
Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
Thomas J Weber, Erik A Imel, Thomas O Carpenter, Munro Peacock, Anthony A Portale
The Journal of Clinical Endocrinology and Metabolism. 2022-12-17
5 citations
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Maria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, Thomas Carpenter, Hae Il Cheong
Calcified Tissue International. 2022-10-01
28 citations
Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.
Kathryn Dahir, María Belén Zanchetta, Irinel Stanciu, Cemre Robinson, Janet Y. Lee
Journal of the Endocrine Society. 2021-09-01

Journal Articles

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...
Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research

Press Mentions

Osteoporosis Screening Guidelines Updated: Do You Need a Bone Scan?January 15th, 2025